Further,
for the in-depth analysis, the report encompasses the industry growth
indicators, restraints, supply and demand risk, along with detailed discussion
on current and future market trends that are associated with the growth of the
market.
The global Duchenne muscular
dystrophy treatment market is
estimated to grow at a CAGR of ~11% over the forecast period, i.e., 2022 –
2030. The market is segmented on the basis of treatment into corticosteroids,
pain management drugs, physical therapy, and others. Out of which, the pain
management drugs segment is anticipated to hold the largest revenue share over the forecast period
owing to the high demand for pain management drugs, as Duchenne muscular
dystrophy can be extremely painful.
Get a Sample PDF
Brochure: https://www.researchnester.com/sample-request-3814
The
global Duchenne
muscular dystrophy or DMD treatment market is anticipated to grow on the back of increasing cases of genetic
muscle-related disorders, backed by poor lifestyle of majority of the
population. According to the data by the
World Health Organization (WHO), over 1.71 billion people suffer from musculoskeletal disorders across the world.
Furthermore, the high share of male population globally, is estimated to propel
the market growth, as DMD is more prevalent in males. According to the data by
the National Organization of Rare Disorders (NORD), 1 in every 3,500 male
suffers from DMD. Moreover, the growing demand for treatment method, and
increasing research activities for development of efficient treatment are
estimated to boost the market growth.
On the basis of geographical analysis, the global
Duchenne
muscular dystrophy treatment
market is segmented into five major regions including North America, Europe, Asia
Pacific, Latin America and Middle East & Africa region. The market in the
North America region is anticipated to gain the largest market share throughout
the forecast period on account of the high health awareness amongst the
population. Moreover, high investment in R&D activities, and presence of
major market players in the region.
The research
is global in nature and covers detailed analysis on the market in North America
(U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium,
Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark],
Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico,
Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South
Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of
Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain,
Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and
Africa). In addition, analysis comprising market size, Y-O-Y growth &
opportunity analysis, market players’ competitive study, investment
opportunities, demand for future outlook etc. has also been covered and
displayed in the research report.
Browse full report
summary : https://www.researchnester.com/reports/duchenne-muscular-dystrophy-treatment-market/3814
High Global Male Population to Boost the
Market Growth
According to
the statistics by the World Bank, in 2020, 50.415% of the global population was
male.
Duchenne muscular dystrophy is a progressive
inherited muscular disease, which is highly prevalent amongst men. This is why,
the high male population across the globe is estimated to boost the market
growth. Moreover, increasing research and development activities in the
healthcare industry is estimated to propel the market growth.
However, complicated and difficult diagnosis
of DMD, and lack of health awareness amongst underdeveloped region are expected
to operate as key restraint to the growth of global Duchenne muscular
dystrophy treatment market over
the forecast period.
This report also provides the existing
competitive scenario of some of the key players of the global Duchenne
muscular dystrophy treatment market which includes company profiling of Eli Lilly and Company, Novartis AG,
Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services,
Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc. The profiling enfolds key information of
the companies which encompasses business overview, products and services, key
financials and recent news and developments. On the whole, the report depicts
detailed overview of the global Duchenne muscular dystrophy
treatment market that will help
industry consultants, equipment manufacturers, existing players searching for
expansion opportunities, new players searching possibilities and other
stakeholders to align their market centric strategies according to the ongoing
and expected trends in the future.
Request
Report Sample@ https://www.researchnester.com/sample-request-3814
Research Nester is a leading service provider for
strategic market research and consulting. We aim to provide unbiased,
unparalleled market insights and industry analysis to help industries,
conglomerates and executives to take wise decisions for their future marketing
strategy, expansion and investment etc. We believe every business can expand to
its new horizon, provided a right guidance at a right time is available through
strategic minds. Our out of box thinking helps our clients to take wise
decision in order to avoid future uncertainties.
Contact for more
Info:
AJ Daniel
Email: info@researchnester.com
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919
No comments:
Post a Comment